Literature DB >> 8639071

Cerebrospinal fluid concentrations of soluble amyloid beta-protein and apolipoprotein E in patients with Alzheimer's disease: correlations with amyloid load in the brain.

T Pirttilä1, P D Mehta, H Soininen, K S Kim, O Heinonen, L Paljärvi, O Kosunen, P Riekkinen, H M Wisniewski.   

Abstract

OBJECTIVE: To compare soluble amyloid beta-protein and apolipoprotein E levels in cerebrospinal fluid (CSF) and brain extracts from patients with definite Alzheimer's disease.
SETTING: University medical center. PATIENTS: Nineteen patients with definite Alzheimer's disease. MAIN OUTCOME MEASURES: Soluble amyloid beta-protein and apolipoprotein E levels in CSF, in neutral and low-pH brain extracts, and in formic acid-treated sections of the frontal, temporal, and cerebellar cortices, measured using enzyme-linked immunosorbent assay.
RESULTS: Soluble amyloid beta-protein and apolipoprotein E levels in CSF were significantly lower in patients with congophilic angiopathy than in those without angiopathy. The levels did not correlate with the number of amyloid plaques in the neocortex. There was, however, a tendency toward an inverse correlation between the amount of amyloid beta-protein in the frontal cortex extracts and the soluble amyloid beta-protein level in CSF.
CONCLUSION: Soluble amyloid beta-protein levels in CSF may reflect amyloid accumulation in brain blood vessels.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8639071     DOI: 10.1001/archneur.1996.00550020105022

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  8 in total

1.  Association of cerebrospinal fluid Aβ42 with A2M gene in cognitively normal subjects.

Authors:  Steven P Millard; Franziska Lutz; Ge Li; Douglas R Galasko; Martin R Farlow; Joseph F Quinn; Jeffrey A Kaye; James B Leverenz; Debby Tsuang; Chang-En Yu; Elaine R Peskind; Lynn M Bekris
Journal:  Neurobiol Aging       Date:  2013-09-04       Impact factor: 4.673

2.  Competitive ELISA studies of neural thread protein in urine in Alzheimer's disease.

Authors:  Susanna Levy; Matthew McConville; Glorie A Lazaro; Paul Averback
Journal:  J Clin Lab Anal       Date:  2007       Impact factor: 2.352

3.  Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of Alzheimer's disease patients.

Authors:  N Rösler; I Wichart; K A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2001       Impact factor: 3.575

Review 4.  The cholinergic neuronal phenotype in Alzheimer's disease.

Authors:  J K Blusztajn; B Berse
Journal:  Metab Brain Dis       Date:  2000-03       Impact factor: 3.584

5.  Biochemical studies in Normal Pressure Hydrocephalus (NPH) patients: change in CSF levels of amyloid precursor protein (APP), amyloid-beta (Aβ) peptide and phospho-tau.

Authors:  Balmiki Ray; Patricio F Reyes; Debomoy K Lahiri
Journal:  J Psychiatr Res       Date:  2010-09-09       Impact factor: 4.791

Review 6.  Review: cerebral microvascular pathology in ageing and neurodegeneration.

Authors:  W R Brown; C R Thore
Journal:  Neuropathol Appl Neurobiol       Date:  2011-02       Impact factor: 8.090

Review 7.  Amyloid Beta and Tau as Alzheimer's Disease Blood Biomarkers: Promise From New Technologies.

Authors:  Lih-Fen Lue; Andre Guerra; Douglas G Walker
Journal:  Neurol Ther       Date:  2017-07-21

Review 8.  Lymphatic Clearance of the Brain: Perivascular, Paravascular and Significance for Neurodegenerative Diseases.

Authors:  Erik N T P Bakker; Brian J Bacskai; Michal Arbel-Ornath; Roxana Aldea; Beatrice Bedussi; Alan W J Morris; Roy O Weller; Roxana O Carare
Journal:  Cell Mol Neurobiol       Date:  2016-03-18       Impact factor: 5.046

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.